Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. - Wikidata - awgldk - TriplyDB

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.

http://www.wikidata.org/entity/Q33404602

about

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia Large granular lymphocytosis during dasatinib therapy The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells.Dasatinib promotes Th1-type responses in granzyme B expressing T-cells The role of dasatinib in the management of chronic myeloid leukemia Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma.The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.Immunology and immunotherapy of chronic myeloid leukemia.Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia.Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection.Neutrophil FcγRIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases.Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib.Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes.Dasatinib promotes the potential of proliferation and antitumor responses of human γδT cells in a long-term induction ex vivo environment.Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia.Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-Vβ+ expansions.Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.Synergistic anti-tumor effects of dasatinib and dendritic cell vaccine on metastatic breast cancer in a mouse model.

P2860

Q26749324-C4C7E437-A0CF-4EE6-8CAE-8E5A050AE036 Q27012699-7620F25E-95E1-4A1A-B7A5-77046DB0CB86 Q33798573-D24ACCCE-3F36-4E95-8978-DAE836353E14 Q33828594-D9AF828B-D83E-4F40-A83E-A4CAE718946C Q33930605-694260E9-0673-4AD6-A944-B56648064B57 Q35087994-A94D9C00-694F-401A-B078-55DBC2C9344E Q37352396-2EFA548C-9C50-419B-87F8-F1A0EB0A726C Q37698857-85AA8080-0A05-47CD-8E88-D6281F515D3D Q38128723-003D457D-7ED1-41D5-A075-C884AE606BA6 Q38175864-89EDD5A1-D67A-41B1-944E-524A4090A946 Q38392673-39A47E29-5673-4188-A894-8C0093712E0F Q39061903-BB5D59E6-D337-4845-AE4D-5B6C9EA0739E Q39226064-3861357C-FD32-4136-A3D4-A9F46906FE22 Q40053971-828C1995-EF88-4464-AEA1-6BD5685374C7 Q40679442-A25BF72A-98EA-44AF-92D3-5A03152D55F7 Q41356321-BC3B10F5-1480-4BBA-8FD2-36A761507F09 Q41767329-C05A47AD-D224-4101-9829-B708A1802150 Q44222188-29C1C7E4-820F-4689-B820-43EBBDF55A4E Q44679459-01BF338F-62D6-43A1-A278-46D178BF8AF4 Q49276933-73490DB2-6F21-4306-9CB9-076315FF6DEF Q49291505-6548BF40-7715-4207-A9CD-0CCD135B83C4 Q53215863-37009BC5-073A-426D-83A0-6AC35206FD56 Q55075934-8B8B4F02-D700-4581-A151-B8606CB9937F

P2860

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.

http://www.wikidata.org/entity/Q33404602

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.

@ast

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.

@en

type

label

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.

@ast

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.

@en

prefLabel

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.

@ast

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.

@en

P1433

Q33404602-4B328CB1-CCBB-497A-9F40-70E6F0E15D65

P1476

Q33404602-3334C3A6-2CCD-4E80-AE62-AF5504014F88

P2093

Q33404602-084B4DDD-2053-43EF-8AC9-E75860B6669D

Q33404602-17343C25-5306-4F54-8A53-AAE7DE652426

Q33404602-22DF5391-5176-4528-A2AC-7D5F2340F278

Q33404602-5073033B-968F-43DC-A8E5-540CB81C9993

Q33404602-620EA411-F23A-4E69-ADA8-AACCFBD6707D

Q33404602-6580C30F-1074-4FCA-8505-82C612171483

Q33404602-71697261-AD04-4BB2-9247-E562FC141EB4

Q33404602-908F12A9-2C38-4E22-87A7-601672E705B9

Q33404602-B1C26930-80D5-4BBF-8D87-8B74EEC87219

Q33404602-B477641B-CD8B-44FA-AAAC-BF76F7514036

P2860

Q33404602-0A8ACAA7-A540-48BA-B5F2-5568F7BA2253

Q33404602-0E58896D-4B81-41B5-A473-453097FA039E

Q33404602-13537AC3-641A-48BF-9481-4B745CCEFC62

Q33404602-1DE5985F-6336-4C8C-A202-13A2E9A756B3

Q33404602-1F509A83-204A-4EB9-A198-B7AFC6DB9116

Q33404602-1F513C65-7A85-4140-9A7C-01BEA7D5A39F

Q33404602-219E6456-802A-4BA2-921C-CBAD6C73F7E5

Q33404602-23DD1519-477C-4B2F-9017-381E4306D324

Q33404602-246F630D-363D-493A-A6AC-C1BBAB06E280

Q33404602-24D73409-C4AC-4FFA-AC49-F6A5ED948546

P2888

Q33404602-E521E948-04FE-4440-A280-A7236F31382C

P304

Q33404602-63E2318F-7FB9-4914-9A53-E5DD74375EC5

P31

Q33404602-C3B959C5-F2C5-4D09-98CA-92A774CDF2FA

P356

Q33404602-F6461178-D00C-44DD-8E68-5CFBB3344C74

P433

Q33404602-26CEE8AB-9B7F-42D1-A6FF-3CACC133A8D3

P478

Q33404602-699EFA1A-316E-4531-B447-DB8CF03985E8

P50

Q33404602-049B3491-95E0-46EA-8FA5-BC3FE2E84A99

Q33404602-7A7D042D-3805-473F-B42C-EEBBAADD6447

Q33404602-A1F97F7E-74B3-4735-8F5B-1612A60B5C81

Q33404602-F7DB9B82-F750-493C-8605-16EC176DEC72

Q33404602-FBBE4636-AB13-4EE9-BDD3-22CA9F19FA80

P577

Q33404602-4D5A69B1-07E3-4BCB-8923-5B4EC85E1BCF

P5875

Q33404602-5400EAAC-876E-4A85-9953-8E563E80CA17

P6179

Q33404602-774CED0A-2E13-4D13-9173-B8C85F09C93D

P698

Q33404602-732AA9CF-CB26-41AE-9416-E07DA6427046

P921

Q33404602-FFB61D17-F031-4447-BAEA-DD20A9DB11BB

P356

P1433

P1476

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy

@en

P2093

A-M Lahesmaa-Korpinen

http://www.w3.org/2001/XMLSchema#string

F Y Lee

http://www.w3.org/2001/XMLSchema#string

J Vakkila

http://www.w3.org/2001/XMLSchema#string

K Auvinen

http://www.w3.org/2001/XMLSchema#string

M Salmi

http://www.w3.org/2001/XMLSchema#string

P Rousselot

http://www.w3.org/2001/XMLSchema#string

R Smykla

http://www.w3.org/2001/XMLSchema#string

S Bouchet

http://www.w3.org/2001/XMLSchema#string

S Hernesniemi

http://www.w3.org/2001/XMLSchema#string

S Jalkanen

http://www.w3.org/2001/XMLSchema#string

P2860

Large-scale data integration framework provides a comprehensive view on glioblastoma multiforme

Mechanisms and functions of Eph and ephrin signalling

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Comprehensive analysis of kinase inhibitor selectivity

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.

P2888

P304

914-924

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2012.348

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Sampsa Hautaniemi

Mathieu Molimard

P577

2012-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233797876

http://www.w3.org/2001/XMLSchema#string

P6179

1014327975

http://www.w3.org/2001/XMLSchema#string

P698

23192016

http://www.w3.org/2001/XMLSchema#string

P921